Mycobacterium tuberculosis treatment modalities and recent insights

Current Drug Delivery

Volumn 11, Issue 6, 2014, Pages 744-752

  Sukhithasri, V ^a   Vinod, Vivek ^a   Varma, Sarath ^a   Biswas, Raja ^a  

^a AMRITA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Antibiotics; Cytokines; Immune response; Intracellular pathogen; Macrophages; Nanoparticles; Tuberculosis

Indexed keywords

AMIKACIN; CAPREOMYCIN; CHITOSAN; CLOFAZIMINE; GENTAMICIN; ISONIAZID; KANAMYCIN; PYRAZINAMIDE; RIFAMPICIN; SOLID LIPID NANOPARTICLE; NANOPARTICLE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL CELL; BACTERIAL CELL WALL; BACTERIAL GENOME; BACTERIAL SURVIVAL; COVALENT BOND; CROSS LINKING; DNA BASE COMPOSITION; DORMANCY; DRUG DELIVERY SYSTEM; GENE MUTATION; GENOME SIZE; HUMAN; IMMUNOMODULATION; MACROPHAGE; MATURATION; MOLECULAR WEIGHT; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHAGOSOME; PRIORITY JOURNAL; PROMOTER REGION; TUBERCULOSIS; ANIMAL; DRUG EFFECTS; MICROBIOLOGY;

ANIMALS; ANTITUBERCULAR AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; NANOPARTICLES; TUBERCULOSIS;

EID: 84926360026     PISSN: 15672018     EISSN: 18755704     Source Type: Journal    
DOI: 10.2174/1567201811666140619121728     Document Type: Article

References (96)

1. Sandhu, G.K. Tuberculosis: current situation, challenges and overview of its control programs in India. J. Glob. Infect. Dis., 2011, 3, 143-150.
2. Zumla, A., Atun, R., Maeurer, M., Mwaba, P., Ma, Z., O'Grady, J., Bates, M., Dheda, K., Hoelscher, M., Grange, J. Viewpoint: Scientific dogmas, paradoxes and mysteries of latent Mycobacterium tuberculosis infection. Trop. Med. Int. Health, 2011, 16, 79-83.
3. Flynn, J.L., Chan, J. Tuberculosis: latency and reactivation. Infect. Immun., 2001, 69, 4195-4201.
4. Somoskovi, A., Dormandy, J., Rivenburg, J., Pedrosa, M., McBride, M., and Salfinger, M. Direct comparison of the genotype MTBC and genomic deletion assays in terms of ability to distinguish between members of the Mycobacterium tuberculosis complex in clinical isolates and in clinical specimens. J. Clin. Microbiol., 2008, 46, 1854-7.
5. Lever, M.S., Williams, A., and Bennett, A.M. Survival of mycobacterial species in aerosols generated from artificial saliva. Lett. Appl. Microbiol., 2000, 31, 238-41.
6. Leemans, J.C., Juffermans, N.P., Florquin, S., van Rooijen, N., Veervordeldonk, M.J., Verbon, A., van Deventor, S.J., van der poll, T. Depletion of alveolar macrophages exerts protective effects in pulmonary tuberculosis in mice. J. Immunol., 2001, 166, 4604-4611.
7. Ferguson, J.S., Weis, J.J., Martin, J.L., and Schlesinger, L.S. Complement protein C3 binding to Mycobacterium tuberculosis is initiated by the classical pathway in human bronchoalveolar lavage fluid. Infect. Immun., 2004, 72, 2564-2573.
8. Russell, D.G. Who puts the tubercle in tuberculosis? Nat. Rev. Microbiol., 2007, 5, 39-47.
9. Ramakrishnan, L. Revisiting the role of the granuloma in tuberculosis. Nat. Rev. Immunol., 2012, 12, 352-366.
10. Ehlers, S., Schaible, U.E. The granuloma in tuberculosis: dynamics of a host-pathogen collusion. Front. Immunol., 2013, 3, 411.
11. Guirado, E., Schlesinger, L.S. Modeling the Mycobacterium tuberculosis Granuloma - the Critical Battlefield in Host Immunity and Disease. Front. Immunol., 2013, 4, 98.
12. Selwyn, P.A., Hartel, D., Lewis, V.A., Schoenbaum, E.E.,Vermund S.H., Klein, R.S., Walker, A.T., Friedland, G.H. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N. Engl. J. Med., 1989, 320, 545-550.
13. Davies, P.D. Drug-resistant tuberculosis. J. R. Soc. Med., 2001, 94, 261-263.
14. Rombouts, Y., Brust, B., Ojha, A.K., Maes, E., Coddeville, B., Elass-Rochard, E., Kremer, L., Guerardel, Y. Exposure of mycobacteria to cell wall-inhibitory drugs decreases production of arabinoglycerolipid related to Mycolyl-arabinogalactan-peptidoglycan metabolism. J. Biol. Chem., 2012, 287, 11060-9.
15. Mishra, A.K., Driessen, N.N., Appelmelk, B.J., and Besra, G.S. Lipoarabinomannan and related glycoconjugates: structure, biogenesis and role in Mycobacterium tuberculosis physiology and hostpathogen interaction. FEMS Microbiol. Rev., 2011, 35, 1126-1157.
16. Crick, D.C., Mahapatra, S., and Brennan, P.J. Biosynthesis of the arabinogalactan-peptidoglycan complex of Mycobacterium tuberculosis. Glycobiology, 2001, 11, 107R-118R
17. Sukhithasri, V., Nisha, N., Biswas, L., Anil, K.V., and Biswas, R. Innate immune recognition of microbial cell wall components and microbial strategies to evade such recognitions. Microbiol. Res., 2013, 168, 396-406.
18. Lavollay, M., Arthur, M., Fourgeaud, M., Dubost, L., Marie, A., Veziris, N., Blanot, D., Gutmann, L., Mainardi, J.L. The peptidoglycan of stationary-phase Mycobacterium tuberculosis predominantly contains cross-links generated by L, Dtranspeptidation. J. Bacteriol., 2008, 190, 4360-6.
19. Weidenmaier, C., Peschel, A. Teichoic acids and related cell-wall glycopolymers in Gram-positive physiology and host interactions. Nat. Rev. Microbiol., 2008, 6, 276-287.
20. Fratti, R.A., Chua, J., Vergne, I., and Deretic, V. Mycobacterium tuberculosis glycosylated phosphatidylinositol causes phagosome maturation arrest. Proc. Natl. Acad. Sci. USA, 2003, 100, 5437-42.
21. Indrigo, J., Hunter, R.L., and Actor, J.K. Influence of trehalose 6, 6'-dimycolate (TDM) during mycobacterial infection of bone marrow macrophages. Microbiology, 2002, 148, 1991-1998.
22. Robinson, N., Kolter, T., Wolke, M., Rybniker, J., Hartmann, P., and Plum, G. Mycobacterial phenolic glycolipid inhibits phagosome maturation and subverts the pro-inflammatory cytokine response. Traffic, 2008, 9, 1936-1947.
23. Indrigo, J., Hunter, R.L., and Actor, J.K. Cord factor trehalose 6, 6'-dimycolate (TDM) mediates trafficking events during mycobacterial infection of murine macrophages. Microbiology, 2003, 149, 2049-2059.
24. Axelrod, S., Oschkinat, H., Enders, J., Schlegel, B., Brinkmann, V., Kaufmann, S.H., Haas, A., Schaible, U.E. Delay of phagosome maturation by a mycobacterial lipid is reversed by nitric oxide. Cell Microbiol., 2008, 10, 1530-45.
25. Ferrari, G., Langen, H., Naito, M., and Pieters, J. A coat protein on phagosomes involved in the intracellular survival of mycobacteria. Cell, 1999, 97, 435-47.
26. Vergne, I., Chua, J., Lee, H.H., Lucas, M., Belisle, J., and Deretic, V. Mechanism of phagolysosome biogenesis block by viable Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA, 2005, 102, 4033-8.
27. Song, H., Huff, J., Janik, K., Walter, K., Keller, C., Ehlers, C., Bossmann, S.H., Niederweis, M. Expression of the ompATb operon accelerates ammonia secretion and adaptation of Mycobacterium tuberculosis to acidic environments. Mol. Microbiol., 2011, 80, 900-18.
28. Vandal, O.H., Nathan, C.F. and Ehrt, S. Acid resistance in Mycobacterium tuberculosis. J. Bacteriol., 2009, 191, 4714-4721.
29. Vergne, I., Chua, J., and Deretic, V. Tuberculosis toxin blocking phagosome maturation inhibits a novel Ca2+/calmodulin-PI3K hVPS34 cascade. J. Exp. Med., 2003, 198, 653-659.
30. Thi, E.P., Reiner, N.E. Phosphatidylinositol 3-kinases and their roles in phagosome maturation. J. Leukoc. Biol., 2012, 92, 553-66.
31. Vergne, I., Fratti, R.A., Hill, P.J., Chua, J., Belisle, J and Deretic, V. Mycobacterium tuberculosis phagosome maturation arrest: mycobacterial phosphatidylinositol analog phosphatidylinositol mannoside stimulates early endosomal fusion. Mol. Biol. Cell 2004, 15, 751-60.
32. Maiti, D., Bhattacharyya, A., and Basu, J. Lipoarabinomannan from Mycobacterium tuberculosis promotes macrophage survival by phosphorylating Bad through a phosphatidylinositol 3-kinase/ Akt pathway. J. Biol. Chem., 2001, 276, 329-33.
33. Koul, A., Herget, T., Klebl, B., and Ullrich, A. Interplay between mycobacteria and host signalling pathways. Nat. Rev. Microbiol., 2004, 2, 189-202.
34. van Crevel, R., Ottenhoff, T.H., and van der Meer, J.W. Innate immunity to Mycobacterium tuberculosis. Clin. Microbiol. Rev., 2002, 15, 294-309.
35. Pai, R.K., Pennini, M.E., Tobian, A.A., Canaday, D.H., Boom, W.H., and Harding, C.V. Prolonged toll-like receptor signaling by Mycobacterium tuberculosis and its 19-kilodalton lipoprotein inhibits gamma interferon-induced regulation of selected genes in macrophages. Infect. Immun., 2004, 72, 6603-14.
36. Harding, C.V., Boom, W.H. Regulation of antigen presentation by Mycobacterium tuberculosis: a role for Toll-like receptors. Nat. Rev. Microbiol., 2010, 8, 296-307.
37. Takeuchi O, Sato S, Horiuchi T, Hoshino K, Takeda K, Dong Z, Modlin RL, Akira S. Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J. Immunol., 2002, 169, 10-4.
38. Hegde, P., Kaveri, S.V., and Bayry, J. Toll-like receptor-2 ligand lipomannan from Mycobacterium tuberculosis does not stimulate inflammatory cytokines in dendritic cells. Aids, 2012, 26, 1182-4, author reply 1184-5.
39. Doz, E., Rose, S., Court, N., Front, S., Vasseur, V., Charron, S., Gilleron M., Puzo, G., Fremaux, I, Delneste, Y., Erard, F., Ryffel, B., Martin, O.R., Quesniaux, V.F. Mycobacterial phosphatidylinositol mannosides negatively regulate host Toll-like receptor 4, MyD88-dependent proinflammatory cytokines, and TRIFdependent co-stimulatory molecule expression. J. Biol. Chem., 2009, 284, 23187-96.
40. Ferwerda, G., Girardin S.E., Kullberg, B.J., Le Bourhis, L., de Jong, D.J., Langenberg, D.M., van Crevel, R., Adema, G.J., Ottenhoff T.H., Van der Meer, J.W., Netea, M.G. NOD2 and toll-like receptors are nonredundant recognition systems of Mycobacterium tuberculosis. PLoS. Pathog., 2005, 1, 279-85.
41. Bonecini-Almeida, M.G., Ho, J.L., Boéchat, N., Huard, R.C., Chitale, S., Doo, H., Geng, J., Rego, L., Lazzarini, L.C., Kritski, A.L., Johnson, W.D. Jr, McCaffrey, T.A., Silva, J.R. Down-modulation of lung immune responses by interleukin-10 and transforming growth factor beta (TGF-beta) and analysis of TGF-beta receptors I and II in active tuberculosis. Infect. Immun., 2004, 72, 2628-2634.
42. Hossain, M.M., Norazmi, M.N. Pattern recognition receptors and cytokines in Mycobacterium tuberculosis infection--the doubleedged sword? Biomed. Res. Int., 2013, 2013, 179-174.
43. Hall, R.G., Leff, R.D. and Gumbo, T. Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy, 2009, 29, 1468-14681.
44. Barbara, E., Johannes, O., Giovanni, B., Migliori, G.S., Ralf, M., Rosella, C., Harald, H., Detlef, K., Tom, S., Sabine, R.-G., Christoph, L. and for the German TBNET Group. Multidrug- and extensively drug-resistant tuberculosis, Germany. Emerg. Infect. Dis., 2008, 14, 1700-1706.
45. Lei, B., Wei, C.J., and Tu, S.C. Action mechanism of antitubercular isoniazid. Activation by Mycobacterium tuberculosis KatG, isolation, and characterization of inha inhibitor. J. Biol. Chem., 2000, 275, 2520-2526.
46. Xu, M., Zhou, Y.N., Goldstein, B.P. and Jin, D.J. Cross-resistance of Escherichia coli RNA polymerases conferring rifampin resistance to different antibiotics. J. Bacteriol., 2005, 187, 2783-92.
47. Zhang, Y., Wade, M.M., Scorpio, A., Zhang, H., and Sun, Z. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J. Antimicrob. Chemother., 2003, 52, 790-795.
48. Goude, R., Amin, A.G., Chatterjee, D., and Parish, T. The arabinosyl transferase EmbC is inhibited by ethambutol in Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2009, 53, 4138-4146.
49. Zheng, J., Rubin, E.J., Bifani, P., Mathys, V., Lim, V., Au, M., Jang, J., Nam, J., Dick, T., Walker, J.R., Pethe, K., Camacho, L.R. Para-Aminosalicylic acid is a prodrug targeting dihydrofolate reductase in Mycobacterium tuberculosis. J. Biol. Chem., 2013, 288, 23447-23456.
50. Zumla, A., Nahid, P., and Cole, S.T. Advances in the development of new tuberculosis drugs and treatment regimens. Nat. Rev. Drug Discov., 12, 388-404.
51. Wang, F., Langley, R., Gulten, G., Dover, L.G., Besra, G.S., Jacobs, W.R., Sacchettini, J.C. Mechanism of thioamide drug action against tuberculosis and leprosy. J. Exp. Med., 2007, 204, 73-8.
52. Bruning, J.B., Murillo, A.C., Chacon, O., Barletta, R.G. and Sacchettini, J.C. Structure of the Mycobacterium tuberculosis Dalanine: D-alanine ligase, a target of the antituberculosis drug Dcycloserine. Antimicrob. Agents Chemother., 2011, 55, 291-301.
53. Cholo, M.C., Steel, H.C., Fourie, P.B., Germishuizen, W.A., and Anderson, R. Clofazimine: current status and future prospects. J. Antimicrob. Chemother., 2011, 67, 290-8.
54. Bozdogan, B., Appelbaum, P.C. Oxazolidinones: activity, mode of action, and mechanism of resistance. Int. J. Antimicrob. Agents 2004, 23, 113-9.
55. Papp-Wallace, K.M., Endimiani, A., Taracila, M.A., and Bonomo, R.A. Carbapenems: past, present, and future. Antimicrob. Agents Chemother., 2011, 55, 4943-49460.
56. Barkan, D., Hedhli, D., Yan, H.G., Huygen, K., and Glickma, M.S. Mycobacterium tuberculosis lacking all mycolic acid cyclopropanation is viable but highly attenuated and hyperinflammatory in mice. Infect. Immun., 2012, 80, 1958-19568.
57. Ohno, H., Kohno, S. Mechanisms of drug-resistance in mycobacteria. Nihon Rinsho., 1998, 56, 3023-3029.
58. Ohno, H., Koga, H., and Kohno, S. Multidrug-resistant tuberculosis. 2. Mechanisms of drug-resistance in Mycobacterium tuberculosis-- genetic mechanisms of drug-resistance. Kekkaku, 1998, 73, 657-663.
59. Sajduda, A., Brzostek, A., Poplawska, M., Auqustynowicz-kopec, E., Zwolska, Z., Niemann, S., Dziadek, J., Hillemann, D.Molecular characterization of rifampin- and isoniazid-resistant Mycobacterium tuberculosis strains isolated in Poland. J. Clin. Microbiol., 2004, 42, 2425-24231.
60. Poudel, A., Nakajima, C., Fukushima, Y., Suzuki, H., Pandey, B.D., Maharjan, B., Suzuki, Y. Molecular characterization of multidrug-resistant Mycobacterium tuberculosis isolated in Nepal. Antimicrob. Agents Chemother., 2012, 56, 2831-2836.
61. Nikolayevsky, V., Brown, T., Balabanova, Y., Ruddy, M., Fedorin, I., and Drobniewski, F. Detection of mutations associated with isoniazid and rifampin resistance in Mycobacterium tuberculosis isolates from Samara Region, Russian Federation. J. Clin. Microbiol., 2004, 42, 4498-502.
62. Wang, F., Massire, C., Li, H., Cummins, L.L., Li, F., Jin, J., Fan, X., Wang, S., Shao, L., Zhang, S., Meng, S., Wu, J., Lu, C., Blyn, L.B., Sampath, R., Ecker, D.J., Zhang, W., Tang, Y.W. Molecular characterization of drug-resistant Mycobacterium tuberculosis isolates circulating in China by multilocus PCR and electrospray ionization mass spectrometry. J. Clin. Microbiol., 2011, 49, 2719-2721.
63. Gandhi, N.R., Nunn, P., Dheda, K., Schaaf, H.S., Zignol, M., van Soolingen, D., Jensen, P., Bayona, J. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet, 2010, 375, 1830-1843.
64. Loewenberg, S. India reports cases of totally drug-resistant tuberculosis. Lancet, 2012, 379, 205.
65. Georghiou, S.B., Magana, M., Garfein, R.S., Catanzaro, D.G., Catanzaro, A., and Rodwell, T.C. Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic review. PLoS One, 2012, 7, e33275.
66. Bang, D., Bengard, A.A., and Thomsen, V.O. Rapid genotypic detection of rifampin- and isoniazid-resistant Mycobacterium tuberculosis directly in clinical specimens. J. Clin. Microbiol., 2006, 44, 2605-2608.
67. Balganesh, M., Dinesh, N., Sharma, S., Kuruppath, S., Nair, A.V. and Sharma, U. Efflux pumps of Mycobacterium tuberculosis play a significant role in antituberculosis activity of potential drug candidates. Antimicrob. Agents Chemother., 2012, 56, 2643-26451.
68. Szumowski, J.D., Adams, K.N., Edelstein, P.H., and Ramakrishnan, L. Antimicrobial Efflux Pumps and Mycobacterium tuberculosis Drug Tolerance: Evolutionary Considerations. Curr. Top Microbiol. Immunol., 2013, 374, 81-108.
69. Rombouts, Y., Brust, B., Ojha, A.K., Maes, E., Coddeville, B., Elass-Rochard, E., Kremer, L, Guerardel, Y. Exposure of mycobacteria to cell wall-inhibitory drugs decreases production of arabinoglycerolipid related to Mycolyl-arabinogalactan-peptidoglycan metabolism. J. Biol. Chem., 2012, 287, 11060-1169.
70. Herbert, D., Paramasivan, C.N., Venkatesan, P., Kubendiran, G., Prabhakar, R and Mitchison, D.A. Bactericidal action of ofloxacin, sulbactam-ampicillin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 1996, 40, 2296-9.
71. Gengenbacher, M., Kaufmann, S.H. Mycobacterium tuberculosis: success through dormancy. FEMS Microbiol. Rev., 2012, 36, 514-32.
72. Ojha, A., Anand, M., Bhatt, A., Kremer, L., Jacobs, W.R., and Hatfull, G.F. GroEL1: a dedicated chaperone involved in mycolic acid biosynthesis during biofilm formation in mycobacteria. Cell, 2005, 123, 861-73.
73. Makhlouf, H.A., Helmy, A., Fawzy, E., El-Attar, M., and Rashed, H.A. A prospective study of antituberculous drug-induced hepatotoxicity in an area endemic for liver diseases. Hepatol. Int., 2008, 2, 353-360.
74. Clemens, D.L., Lee, B.Y., Xue, M., Thomas, C.R., Meng, H., Ferris, D., Nel, A.E., Zink, J.I., Horwitz, M.A. Targeted intracellular delivery of antituberculosis drugs to Mycobacterium tuberculosisinfected macrophages via functionalized mesoporous silica nanoparticles. Antimicrob. Agents Chemother., 2012, 56, 2535-25345.
75. Griffiths, G., Nystrom, B., Sable, S.B., and Khuller, G.K. Nanobead- based interventions for the treatment and prevention of tuberculosis. Nat. Rev. Microbiol., 2010, 8, 827-834.
76. Sosnik, A., Carcaboso, A.M., Glisoni, R.J., Moretton, M.A. and Chiappetta, D.A. New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery. Adv. Drug Deliv. Rev., 2010, 62, 547-559.
77. Saito, H., Tomioka, H. Therapeutic efficacy of liposome-entrapped rifampin against Mycobacterium avium complex infection induced in mice. Antimicrob. Agents Chemother., 1989, 33, 429-433.
78. Deol, P., Khuller, G.K., and Joshi, K. Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice. Antimicrob. Agents Chemother., 1997, 41, 1211-1214.
79. Adams, L.B., Sinha, I., Franzblau, S.G., Krahenbuhl. J.L., and Mehta, R.T. Effective treatment of acute and chronic murine tuberculosis with liposome-encapsulated clofazimine. Antimicrob. Agents Chemother., 1999, 43, 1638-1643.
80. Klemens, S.P., Cynamon, M.H., Swenson, C.E., and Ginsberg, R.S. Liposome-encapsulated-gentamicin therapy of Mycobacterium avium complex infection in beige mice. Antimicrob. Agents Chemother., 1990, 34, 967-970.
81. Pandey, R., Sharma, A., Zahoor, A., Sharma, S., Khuller, G.K., and Prasad, B. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J. Antimicrob. Chemother., 2003, 52, 981-986.
82. Ul-Ain, Q., Sharma, S., and Khuller, G.K. Chemotherapeutic potential of orally administered poly(lactide-co-glycolide) microparticles containing isoniazid, rifampin, and pyrazinamide against experimental tuberculosis. Antimicrob. Agents Chemother., 2003, 47, 3005-3007.
83. Soto, E.R., Caras, A.C., Kut, L.C., Castle, M.K., and Ostroff, G.R. Glucan particles for macrophage targeted delivery of nanoparticles. J. Drug. Deliv., 2011, 2012, 143524.
84. Patel, B.K., Parikh, R.H., and Aboti, P.S. Development of oral sustained release rifampicin loaded chitosan nanoparticles by design of experiment. J. Drug Deliv., 2013, 2013, 370938.
85. Qurrat, ul A., Sharma, S., Khuller, G.K., and Garg, S.K. Alginate-based oral drug delivery system for tuberculosis: pharmacokinetics and therapeutic effects. J. Antimicrob. Chemother., 2003, 51, 931-938.
86. Pandey, R., Khuller, G.K. Chemotherapeutic potential of alginatechitosan microspheres as anti-tubercular drug carriers. J. Antimicrob. Chemother., 2004, 53, 635-640.
87. Clemens, D.L., Lee, B.Y., Xue, M., Thomas, C.R., Meng, H., Ferris, D., Nel, A.E., Zink, J.I., Horwitz, M.A. Targeted intracellular delivery of antituberculosis drugs to Mycobacterium tuberculosisinfected macrophages via functionalized mesoporous silica nanoparticles. Antimicrob. Agents Chemother., 2012, 56, 2535-45.
88. Johnson, C.M., Pandey, R., Sharma, S., Khuller, G.K., Basaraba, R.J., Orme, I.M., Lenaerts, A.J. Oral therapy using nanoparticleencapsulated antituberculosis drugs in guinea pigs infected with Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2005, 49, 4335-8.
89. Sharma, A., Pandey, R., Sharma. S. and Khuller, G. K. Chemotherapeutic efficacy of poly (DL-lactide-co-glycolide) nanoparticle encapsulated antitubercular drugs at sub-therapeutic dose against experimental tuberculosis. Int. J. Antimicrob. Agents, 2004, 24, 599-604.
90. Peters, K., Leitzke, S., Diederichs, J.E., Borner, K., Hahn, H., Müller, R.H., Ehlers, S. Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. J. Antimicrob. Chemother., 2000, 45, 77-83.
91. Ahmad, Z., Sharma, S., and Khuller, G.K. Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. Int. J. Antimicrob. Agents, 2005, 26, 298-303.
92. Ahmad, Z., Pandey, R., Sharma, S., and Khuller, G.K. Alginate nanoparticles as antituberculosis drug carriers: formulation development, pharmacokinetics and therapeutic potential. Indian J. Chest Dis. Allied. Sci., 2006, 48, 171-6.
93. Verma, R.K., Kaur, J., Kumar, K., Yadav, A.B. and Misra, A. Intracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice. Antimicrob. Agents Chemother., 2008, 52, 3195-201.
94. Sharma, R., Muttil, P., Yadav, A.B., Rath, S.K., Bajpai, V.K., Mani, U., Misra, A. Uptake of inhalable microparticles affects defence responses of macrophages infected with Mycobacterium tuberculosis H37Ra. J. Antimicrob. Chemother., 2007, 59, 499-506.
95. Garcia-Contreras, L., Sethuraman, V., Kazantseva, M., Godfrey, V., and Hickey, A.J. Evaluation of dosing regimen of respirable rifampicin biodegradable microspheres in the treatment of tuberculosis in the guinea pig. J. Antimicrob. Chemother., 2006, 58, 980-6.
96. Kumar, G., Malhotra, S., Shafiq, N., Pandhi, P., Khuller, G.K., and Sharma, S. In vitro physicochemical characterization and short term in vivo tolerability study of ethionamide loaded PLGA nanoparticles: potentially effective agent for multidrug resistant tuberculosis. J. Microencapsul., 2011, 28(8), 717-728.